Use of Lck inhibitors for treatment of immunologic diseases

US7989474B2 · kind B2 · utility

Assignee

• BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG · DE

Inventors

• Gerald Juergen Roth · Biberach, DE
• Armin Heckel · Biberach an der Riß, DE
• Rainer Walter · Biberach, DE
• Frank Hilberg · Wien, AT
• Rudolf Hauptmann · Ebreichsdorf, AT
• Martin Fredrich Stefanic · Biberach an der Riß, DE
• Florian Colbatzky · Stafflangen, DE
• Steffan Ernest · Mölnlycke, SE

Key dates

• Filing date: Dec 12, 2008
• Grant date: Aug 2, 2011
• Expiry date: Aug 5, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.